Item 5.02 Departures of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.



(e)

First-Half 2023 Corporate Goals

Our named executive officers are eligible to receive annual performance-based bonuses pursuant to their letter agreements with us. The annual performance-based bonus each named executive officer is eligible to receive is generally based on the extent to which we achieve corporate goals that our Board of Directors (the "Board") establishes each year. Following the end of each year, the Board reviews our performance against each corporate goal and determines the extent to which we achieved each of our corporate goals.

On February 2, 2023, the Board adopted first-half 2023 corporate goals for purposes of determining the eligibility of our named executive officers to receive performance-based bonuses for 2023. The Board anticipates adopting the second-half 2023 corporate goals mid-year. The first-half goals are expected to be weighted at approximately 50% of all 2023 corporate goals. The first-half corporate goals relate to the following categories: financial goals, including profiling revenue and cash management, and a drug discovery business development goal.

Certain of the corporate goals contain minimum achievement levels that must be satisfied in order to earn the portion of the bonus attributable to such goal, but there is no aggregate minimum percentage of corporate goals that must be achieved in order to earn a bonus. No specific individual goals were established for any of the named executive officers for the first half of 2023.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses